Orbus Therapeutics Lands $32,500,000 Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d6f84c41-c34e-433d-b261-bcdac3c66b48 - Date
8/21/2015 - Company Name
Orbus Therapeutics - Mailing Address
1043 Via Tornasol Palo Alto, CA 95003 USA - Company Description
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. - Website
http://www.orbustherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$32,500,000 - Transaction Round
Series A - Proceeds Purposes
The funding will enable Orbus Therapeutics to conduct a Phase 3 clinical trial evaluating its promising therapeutic product candidate, eflornithine. - M&A Terms
- Venture Investor
Longitude Capital Management - Venture Investor
H.I.G. Capital - Venture Investor
Adams Street Partners
